𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A Pyrophosphate-Responsive Gadolinium(III) MRI Contrast Agent

✍ Scribed by Dr. Andrew J. Surman; Dr. Célia S. Bonnet; Dr. Mark P. Lowe; Gavin D. Kenny; Prof. Jimmy D. Bell; Dr. Éva Tóth; Dr. Ramon Vilar

Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
420 KB
Volume
17
Category
Article
ISSN
0947-6539

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Gadolinium (III) complex equilibria: The
Gadolinium (III) complex equilibria: The implications for Gd(III) MRI contrast agents
✍ Graham E. Jackson; Sinclair Wynchank; Marianne Woudenberg 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 561 KB

## Abstract A computer model of blood plasma which has allowed the effect of Gd(III) contrast agents to be simulated has been developed. Initial binding of Gd(III) is to transferrin. At high concentration the metal ion binds to citrate and salicylate. At a concentrate of 10^−3^ __M__, GdCl~3~ is pr

Paramagnetic iron (III) MRI contrast age
Paramagnetic iron (III) MRI contrast agents
✍ David L. White 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 289 KB

## Abstract The advantages and disadvantages of a number of paramagnetic Fe(III)‐containing MRI contrast agents are discussed. © 1991 Academic Press, Inc.

Novel radical-responsive MRI contrast ag
Novel radical-responsive MRI contrast agent based on paramagnetic liposomes
✍ Christian Gløgård; Gry Stensrud; Silvio Aime 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 113 KB

## Abstract A novel, radical responsive MRI contrast agent based on a gadolinium chelate conjugated to a liposome through a disulfide linker was synthesized, with the aim of pursuing the __in vivo__ mapping of radicals. The liposome was prepared by incorporating a thiol‐activated phospholipid, whic

Response to: Safety risks with gadoliniu
Response to: Safety risks with gadolinium-based contrast agents
✍ Honglei Zhang; Jeffrey H. Maki; Martin R. Prince 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 29 KB

We are grateful to Drs. Marzella, Blank, Gelperin, and Johann-Liang of the U.S. Food and Drug Administration for providing a timely update/reminder on the evolving safety concerns related to gadolinium and especially to Gadodiamide's association with nephrogenic systemic fibrosis (NSF) as well as th